Tirzepatide Side Effects: A Pharmacovigilance Guide for Patients and Prescribers

Updated: 2026-05-06

In SURMOUNT-1, only 4.3% to 7.1% of tirzepatide-treated participants discontinued the drug because of an adverse event, depending on dose (NEJM 2022, SURMOUNT-1). The clinical headline is that most patients tolerate tirzepatide. The pharmacovigilance headline is that the small group who do not deserve a clear, sourced playbook for what is normal, concerning, and emergent.

This guide covers tirzepatide side effects for patients on either branded Mounjaro and Zepbound or compounded tirzepatide from a 503A pharmacy. It separates titration-phase symptoms from labeled serious risks, layers in the compounded-product variables patients searching online often miss, and points to the regulatory and clinical sources behind each claim. For readers comparing telehealth options, VST maintains a parallel resource of providers ranked by safety + adverse-event response.

The guide is organized around a four-category framework, a dose-by-dose timeline, a symptom-by-symptom reference, and an action sequence. Most readers will only need the first half. The second half exists because postmarketing surveillance, per recent JCEM Case Reports, is still uncovering presentations the trials did not catch (JCEM Case Reports 2025).

Why Compounded GLP-1 Adverse Events Need Their Own Framework

The FDA's own consumer-facing page is unambiguous: compounded GLP-1 drugs are not FDA-approved, the agency does not review them for safety, effectiveness, or quality, and reports of dosing errors and salt-form confusion have already accumulated in the agency's surveillance system (FDA, Concerns with Unapproved GLP-1). For patients, that is the most important sentence on this page.

Branded Mounjaro and Zepbound carry a single supply chain. Each batch is produced under current Good Manufacturing Practice, tested for potency and impurities, and tied to a manufacturer legally required to collect adverse-event reports and submit them to FDA. The adverse-event picture for those products is the picture in the prescribing information.

Compounded tirzepatide does not inherit that infrastructure. The category is split between 503A pharmacies, which compound patient-specific prescriptions without GMP-equivalent oversight, and 503B outsourcing facilities, which operate to higher standards but still produce non-FDA-approved product (FDA, Concerns with Unapproved GLP-1). Most telehealth-distributed compounded tirzepatide is 503A. Concentrations vary by pharmacy, additives such as cyanocobalamin or methylcobalamin are sometimes mixed in, and inter-batch testing is not standardized.

Eli Lilly published an open letter documenting impurities, bacterial contamination, and elevated endotoxin in tested samples of compounded tirzepatide combined with vitamin B12, and stated that nothing is known about the human safety profile of the resulting chemical impurity (Eli Lilly Open Letter on Compounded Tirzepatide). That is the compounded-specific safety layer that does not exist for branded product.

The other consequence is reporting. Manufacturer-driven pharmacovigilance does not exist for compounded products. The only signal-collection mechanism available to FDA is the voluntary MedWatch report from the patient or provider, covered later in this guide.

The Four Categories of Tirzepatide Adverse Events

A useful mental model maps every symptom a patient could feel onto one of four categories. Most patients only experience symptoms in category one. The framework tells a patient, in real time, whether to ride out a symptom, call the prescriber, or escalate to emergency care.

1. Common (usually self-limiting, dose-dependent)

Gastrointestinal symptoms dominate. Per Mounjaro PI Section 6, nausea occurred in 12% (5 mg), 15% (10 mg), and 18% (15 mg) of treated patients vs 4% on placebo; diarrhea 12-17%; vomiting 5-9%; constipation 6-7%; dyspepsia 5-8%; abdominal pain 5-6%; decreased appetite 5-11%. In the obesity population, Zepbound nausea rates ran higher, up to roughly 31% in SURMOUNT-1 (NEJM 2022, SURMOUNT-1). These cluster around dose escalations and typically resolve within one to two weeks of holding at the prior dose. Fatigue, headache, and injection-site reactions also fall here.

2. Concerning (call provider same day)

Symptoms in this bucket warrant a same-day call to the prescribing provider, not the emergency room, unless they meet the red-flag criteria in Section 11. Examples include severe or persistent abdominal pain that has not been clearly worked up, dehydration from vomiting that prevents fluid intake, gallbladder-region pain, hypoglycemia symptoms in patients on a sulfonylurea or insulin, new vision changes, and signs of acute kidney injury such as decreased urination or new lower-extremity swelling (Mounjaro PI, Section 5). The threshold for "same day" is whether the symptom has changed character or intensity in a way that does not fit the titration pattern.

3. Serious labeled risks (boxed warning and monitored signals)

Mounjaro carries a boxed warning for thyroid C-cell tumors. The label states verbatim: "Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined" (Mounjaro PI, Boxed Warning). The drug is contraindicated in patients with personal or family history of MTC or with MEN-2.

Other labeled serious risks: pancreatitis (Mounjaro PI Section 5.2: discontinue promptly if suspected), acute gallbladder disease (0.6% vs 0% placebo per Mounjaro PI), acute kidney injury linked to dehydration from GI losses, hypersensitivity reactions including anaphylaxis and angioedema (3.2% vs 1.7% placebo per Mounjaro PI), worsening of pre-existing diabetic retinopathy, and a class-level NAION signal (JAMA Network Open 2025, Hathaway/Sodhi/Etminan cohort).

4. Compounded-specific (added by the compounding step)

This category exists only for compounded tirzepatide. It includes warm-vial potency loss during shipment, dosing errors from non-standard concentrations across pharmacies, ingredient mix-ups (one Trustpilot complaint documents an Eden customer who paid $576 expecting tirzepatide and received MIC plus methylfolate vials, per Trustpilot at the time of writing), additive reactions to cyanocobalamin or B-complex add-ons, and impurities documented in Lilly's open letter (Eli Lilly Open Letter on Compounded Tirzepatide).

Most patients will land in category one. The framework exists for the moments when they do not.

Recognition: Nausea vs Pancreatitis vs Thyroid Concerns

GLP-1 titration nausea and early pancreatitis can feel similar in the first 48 hours, and that is the recognition problem most likely to drive an avoidable hospital admission or, conversely, an avoidable ER bypass.

GI titration nausea clusters in the 24-to-72-hour window after injection or dose increase. It is typically dull, wave-like, improves with hydration and small low-fat meals, and resolves within one to two weeks at a stable dose. Onset patterns from prescribing information place peak nausea at 24 to 48 hours, peak vomiting one to two days after that, and peak diarrhea around day four (Mounjaro PI, Section 6).

Pancreatitis differential looks different. Severe, constant epigastric pain that often radiates to the back, frequently with persistent vomiting, sometimes with low-grade fever and tachycardia, not relieved by antacids or position change. Per Mounjaro PI Section 5.2, prescribers should "discontinue promptly" if pancreatitis is suspected. Multi-society perioperative guidance (AGA/ASMBS/ASA, October 2024) does not mandate routine GLP-1 holds before procedures but recommends individualized risk assessment.

Thyroid concerns present as a new neck mass, persistent hoarseness, dysphagia, or sustained throat fullness. Most cases reported on telehealth forums turn out to be unrelated to MTC, but the pattern still warrants provider evaluation. The Mounjaro label notes that monitoring with serum calcitonin or thyroid ultrasound is "of uncertain value" in average-risk patients, and ATA does not recommend routine pre-treatment calcitonin screening (ATA/JCEM 2025).

For the full triage protocol, including emergency-vs-portal decision rules, see how to recognize adverse events.

Tirzepatide Side Effect Timeline: Day 1 Through Long-Term Use

The first injection rarely produces day-one side effects. The fourth injection often does. Most patients beginning tirzepatide expect the first dose to feel like the worst dose, and the dose-escalation pattern is the opposite.

Day 1 (first injection at 2.5 mg). Day-one tirzepatide side effects are typically mild or absent. Nausea onset most often falls between four and 24 hours, peaks at 24 to 48 hours, then resolves over two to four days (Mounjaro PI clinical pharmacology). Subcutaneous tirzepatide reaches peak plasma concentration 24 to 72 hours post-injection, which is why the symptom curve trails the dose.

Week 1 to 4 (2.5 mg starter dose). The 2.5 mg dose is a tolerability dose, not a therapeutic one. Mild GI symptoms peak three to five days after injection and typically ease before the next weekly dose (Mounjaro PI, Section 6). Most patients clear this window without needing dose adjustment.

Week 4 (titration to 5 mg). The first step-up is the most common point at which patients re-experience the GI cluster, often with greater intensity than during the starter phase. Sound clinical practice is to hold the step-up if symptoms have not resolved at the prior dose. Patients who push through escalations against persistent symptoms are the cohort most likely to wind up with dehydration-driven complications.

Month 2 to 6 (5 mg, 7.5 mg, 10 mg). Each subsequent escalation can re-trigger nausea, diarrhea, or constipation. Weight loss accelerates; SURMOUNT-1 reported a -15.0% mean weight change at 5 mg by 72 weeks (NEJM 2022, SURMOUNT-1). Hair shedding may begin around month three, most consistent with telogen effluvium from rapid weight loss rather than a direct follicular effect. Gallbladder symptoms, when they occur, also tend to surface in this window.

Month 6 to 12 (10 or 15 mg maintenance). Most patients settle at 10 or 15 mg. Long-term concerns to monitor include gallbladder symptoms, vision changes, mood changes, and micronutrient status. SURMOUNT-1 reported -20.9% mean weight change at 15 mg by 72 weeks (NEJM 2022, SURMOUNT-1). This is also the window in which JCEM Case Reports documented unanticipated presentations including palpitations and persistent morning headaches in compounded users (JCEM Case Reports 2025).

Beyond 12 months. Long-term safety data on tirzepatide is limited compared with first-generation GLP-1s. SURMOUNT-4 documented substantial weight regain after discontinuation. The boxed thyroid warning is theoretical (rodent-derived), but ongoing awareness of neck mass, hoarseness, and dysphagia is recommended.

Discontinuation. Appetite and a portion of weight loss return within weeks; no withdrawal syndrome has been characterized in trials.

For a printable dose-by-dose map, see side effect timeline from day 1 onward.

Specific Tirzepatide Side Effects: A Symptom-by-Symptom Reference

Below are the side effects patients search most often, with what is documented in the labeling and trial literature, what is still under investigation, and what recent postmarketing surveillance has added.

Tirzepatide Side Effects: Pancreatitis

Mounjaro PI Section 5.2 carries the formal warning for acute pancreatitis, including fatal and non-fatal hemorrhagic and necrotizing presentations, in GLP-1 receptor agonist users. The label instructs prescribers to discontinue tirzepatide if pancreatitis is suspected and pursue lipase and imaging (Mounjaro PI, Section 5.2). SURMOUNT-1 reported four adjudication-confirmed cases across treatment and placebo groups, none severe (NEJM 2022, SURMOUNT-1). Background incidence in the general population is roughly 13 to 45 cases per 100,000 person-years; a tirzepatide-specific causal effect is not established. The recognition rule is symptom-driven: severe constant epigastric pain radiating to the back, often with persistent vomiting and not relieved by antacids or position change, warrants immediate evaluation and dose discontinuation. Mild diffuse abdominal discomfort during titration is a different presentation; patients should bypass the portal for the back-radiating pattern.

Tirzepatide Eye Side Effects and Tirzepatide Vision Side Effects

The Mounjaro label warns that rapid glycemic improvement can transiently worsen pre-existing diabetic retinopathy and that patients with a retinopathy history should be monitored for progression (Mounjaro PI, Section 5.6). A separate class-level signal involves non-arteritic anterior ischemic optic neuropathy, or NAION. A 2025 JAMA Network Open cohort of 159,398 propensity-matched patients with type 2 diabetes found NAION in 0.04% of those on semaglutide or tirzepatide vs 0.02% in matched comparators (HR 1.76; 95% CI 1.01-3.07), with other optic-nerve disorders also elevated (HR 1.65) (JAMA Network Open 2025, Hathaway/Sodhi/Etminan). Absolute risk remains low; patients with prior optic-nerve disease should weigh the signal with their ophthalmologist before initiation. Sudden vision loss in one or both eyes is a 911-level symptom and warrants emergency evaluation rather than a portal message.

Tirzepatide Side Effects: Thyroid

The boxed warning derives from rodent C-cell tumor findings; the human relevance is unknown (Mounjaro PI, Boxed Warning). Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or with MEN-2. Patients should be counseled on neck mass, dysphagia, dyspnea, and persistent hoarseness as symptoms warranting evaluation (Mounjaro PI, Patient Counseling). The label describes calcitonin and ultrasound monitoring in average-risk patients as "of uncertain value," and the American Thyroid Association does not recommend routine pre-treatment calcitonin screening due to false-positive concerns and low positive predictive value (ATA/JCEM 2025). Most neck-fullness presentations on telehealth forums turn out to be reflux-related or muscular, but the pattern still warrants provider evaluation. Patients with a new neck mass should call the provider same day; emergency care is reserved for airway involvement.

Tirzepatide Side Effects: Cancer

Outside the rodent-derived thyroid boxed warning, no human cancer signal has been demonstrated for tirzepatide in the SURMOUNT or SURPASS programs (NEJM 2022, SURMOUNT-1; NEJM 2021, SURPASS-2). Earlier-era pancreatic cancer concerns linked to exenatide were not borne out in subsequent meta-analyses. The honest framing is the gap between "the signal that is monitored" (thyroid C-cell, theoretical and rodent-derived) and "the signals tested and not found" (other malignancies in the trial programs). The contraindication for personal or family history of MTC and for MEN-2 remains binding regardless of monitoring status; providers should obtain that history at intake. Routine pre-treatment cancer screening beyond standard age-appropriate screening is not currently recommended (ATA/JCEM 2025). Patients with new or persistent neck symptoms should pursue evaluation per the thyroid section above.

Tirzepatide Side Effects: Anxiety, Mood, and Suicidality

In January 2024, FDA reviewed available data on GLP-1 receptor agonists across 91 placebo-controlled trials covering 107,910 patients and found no causal association with suicidal thoughts or actions (FDA, Drug Safety Communication 2024). The agency subsequently requested removal of the suicidality warning from GLP-1 labeling, and EMA reached a similar conclusion. Patients with prior depression or anxiety should monitor mood and report changes, and clinicians should distinguish between mood change driven by rapid body composition shifts or restrictive eating patterns and a direct medication effect. Patients who experience new or worsening suicidal thoughts at any point should call or text 988 (Suicide and Crisis Lifeline) and notify the prescribing provider the same day, regardless of the FDA's labeling conclusion.

Tirzepatide Hair Loss Side Effects

In SURMOUNT-1, alopecia rates were dose-dependent: 5.7% at 15 mg, 4.1% at 10 mg, and 2.8% at 5 mg, vs 1.0% on placebo, and the signal was concentrated in women (up to roughly 7.1% in female participants vs under 1% in men) (NEJM 2022, SURMOUNT-1). The mechanism most consistent with the data is telogen effluvium triggered by rapid weight loss and caloric restriction rather than a direct follicular effect; EMA labeling and a pooled SURMOUNT analysis attribute the signal to rate of weight reduction (Diabetes, Obesity & Metabolism 2025 pooled analysis). Hair typically regrows within six to 12 months of weight stabilization. Adequate protein intake plus iron and vitamin D status checks are reasonable supportive steps. Persistent shedding past 12 months warrants dermatology referral and a workup for non-drug causes.

Tirzepatide Side Effects: Headache

Headache is reported by roughly 10% to 15% of tirzepatide users during early titration in published clinical reviews, typically resolving within four to six weeks. The mechanism is multifactorial: dehydration from GI losses, reduced fluid intake during nausea, and, when tirzepatide is combined with a sulfonylurea or insulin, occult hypoglycemia (Mounjaro PI, Section 5). First-line management is hydration and a dose-hold at the previous step until symptoms resolve. Patients on insulin or sulfonylureas should self-check glucose before assuming a headache is dehydration-driven; a fingerstick under 70 mg/dL changes the call. Severe or new-pattern headaches, particularly with vision change, confusion, or weakness, bypass the portal and warrant emergency evaluation. Persistent dull headache that does not respond to fluids and dose-hold should be discussed with the provider before the next dose.

Tirzepatide With B12 Side Effects and Other Compound Additives

Some 503A pharmacies add cyanocobalamin (B12), methylcobalamin, or B-complex vitamins to compounded tirzepatide, often marketed as "lipotropic" add-ons. Reactions reported in patient review surfaces include injection-site pain (cyanocobalamin is acidic), facial flushing, and transient anxiety. The cyanocobalamin label warns of hypokalemia, including fatal cases, due to potassium uptake during hematopoiesis, and recommends monitoring potassium (Cyanocobalamin product labeling).

The pharmacovigilance concern is broader than additive reactions. Eli Lilly's open letter documented impurities exceeding ICH Q3B thresholds, plus bacterial contamination and elevated endotoxin, in tested samples of compounded tirzepatide combined with B12, and stated that the human safety profile of the resulting impurity is unknown, with no data on receptor binding, toxicity, or immune reactions (Eli Lilly Open Letter on Compounded Tirzepatide). Branded Mounjaro and Zepbound contain tirzepatide plus standard excipients only.

A 2025 JCEM Case Reports series documented previously unrecognized presentations in compounded users, including a 38-year-old woman who developed palpitations, chest discomfort, myalgia, tachycardia (HR 130), and hypotension within 24 hours of switching from semaglutide to tirzepatide 5 mg, plus two additional cases of persistent neck and back pain with morning headaches 24 to 72 hours post-injection (JCEM Case Reports 2025).

For the full additive map and which providers add what, see how compound formulation affects side effects.

Related Safety Topics in the VST GLP-1 Library

Each adverse-event topic in this guide has a dedicated bridge page that goes deeper.

• how to recognize adverse events
• side effect timeline from day 1 onward
• how compound formulation affects side effects
• how to file a MedWatch report
• why compounded drug variability matters
• red flags that mean stop your GLP-1

What to Do When You Experience an Adverse Event

There is a sequence, and it is not optional. The provider call comes first for non-emergency symptoms, the MedWatch report comes second, and emergency care substitutes for the provider call when symptoms meet the red-flag criteria below.

1. Document. Write down what you felt, when it started, what dose you were on, when you last injected, and what you ate or drank that day. Photos of the injection site, vial, and label help, particularly for compounded products where lot numbers are not always retrievable later.
2. Contact the prescribing provider via portal or phone. Most telehealth providers commit to a 24-to-48-hour response window; verified-safe providers in the VST audit often respond same day. If the provider cannot be reached and the symptom is escalating, escalate care without waiting.
3. File a MedWatch report. Even after the provider responds, file the report. Provider-side reporting to FDA is voluntary, and compounded products have no manufacturer-level pharmacovigilance pipeline. The patient's report is often the only signal FDA will receive.

For red-flag symptoms, step two is skipped entirely. For provider responsiveness as a quality signal, see the Provider Response Patterns section below.

How to File a MedWatch Report for Tirzepatide Adverse Events

A consumer MedWatch report takes roughly 15 to 20 minutes and feeds every FDA safety review that touches the drug class. There are three submission paths:

• Online: the FDA MedWatch online voluntary reporting portal walks consumers through Form FDA 3500B, the plain-language version available in English and Spanish PDFs (FDA MedWatch program).
• Phone: 1-800-FDA-1088 to request a paper form.
• Fax or mail: fax 1-800-FDA-0178, or mail to MedWatch Program, FDA, 10903 New Hampshire Ave., Bldg 22 G0207, Silver Spring, MD 20993.

What to include: patient demographics (no name required), medication name (specify "compounded tirzepatide" if applicable, with the dispensing pharmacy name and lot number where available), dose and start date, the adverse event with date of onset and severity, the outcome (hospitalization, ED visit, ongoing symptoms, resolution), and concurrent medications.

For compounded drugs, the pharmacy of origin and any added ingredients (cyanocobalamin, B-complex, methylfolate, MIC) should be included. This is the only mechanism by which FDA can correlate a signal across multiple patients of the same pharmacy.

Reports can be anonymous. There is no cost or legal exposure. A few reports tied to one pharmacy can trigger an FDA inspection; without those reports, harm continues invisibly.

For step-by-step screenshots and the consumer form walkthrough, see how to file a MedWatch report.

Why Patient MedWatch Reports Matter More for Compounded Tirzepatide

For Mounjaro and Zepbound, Eli Lilly is required to collect, analyze, and report adverse events to FDA across every batch. For compounded tirzepatide from 503A pharmacies, no entity carries that obligation at an equivalent level.

Three structural facts drive the asymmetry. First, 503A pharmacies are not subject to AERS-equivalent manufacturer reporting requirements. Second, compounded products are produced patient-by-patient, often weekly, with no inter-batch testing requirement at the 503B level, let alone branded manufacturing. Third, the only national signal-collection mechanism for compounded GLP-1 adverse events is FAERS, which depends on voluntary patient and provider reports.

A small number of well-documented patient reports tied to one pharmacy can trigger an FDA inspection and public communication. Without those reports, a problematic batch or pharmacy may continue to ship. The FDA's "Concerns with Unapproved GLP-1" page documents adverse events traced to dosing errors and salt-form confusion (FDA, Concerns with Unapproved GLP-1), and Lilly's open letter documented impurities and contamination in tested samples (Eli Lilly Open Letter on Compounded Tirzepatide). Both data trails depend on reporting.

For the full pharmacovigilance data flow comparison, see why compounded drug variability matters.

Red Flags That Mean Stop Tirzepatide and Seek Emergency Care

The following symptoms are 911-level. Do not wait for the provider portal to respond.

• Severe, constant abdominal pain radiating to the back (possible pancreatitis)
• Persistent vomiting preventing fluid intake for more than 12 hours
• Sudden vision loss in one or both eyes (possible NAION)
• Severe allergic reaction: facial swelling, throat tightness, rapidly spreading hives, difficulty breathing (anaphylaxis)
• Severe right-upper-quadrant pain with fever (possible acute cholecystitis)
• Yellowing of skin or eyes (possible biliary obstruction)
• Sudden, severe headache with vision changes or confusion
• Decreased urination, leg swelling, or dark-colored urine (possible acute kidney injury)
• New neck mass or lump with persistent hoarseness or trouble swallowing (call provider same day; emergency only if airway is involved)
• Chest pain or shortness of breath
• Suicidal thoughts (call or text 988; tell your provider the same day)

When in doubt, go. Hospital evaluation for a benign symptom is a smaller cost than a missed pancreatitis or NAION. For the printable checklist, see red flags that mean stop your GLP-1.

Provider Response Patterns: Which Telehealth Providers Handle Tirzepatide Adverse Events Well

A provider's response to adverse events is the single best forward indicator of safety, and it is publicly visible in BBB, Trustpilot, and court filings. The profiles below use data captured during the VST audit; numbers shift, so re-check live profiles before any purchase decision.

Henry Meds

Per the BBB snapshot used for this audit, Henry Meds (Adonis Health Inc.) holds an F rating, is not BBB-accredited, and shows 192 complaints filed in the prior three years with 25 unanswered. Per Trustpilot at the time of writing, the page shows 4.5 out of 5 across more than 12,000 reviews but carries a Trustpilot-issued notice indicating suspected inauthentic review patterns.

On April 23, 2025, Eli Lilly filed suit against Henry Meds and other telehealth providers in the U.S. District Court for the Northern District of California. The complaint alleges Henry Meds "deceives consumers about its untested, unapproved drugs, risking patient safety," and Lilly's filing asserts that the company sold an oral pill formulation of tirzepatide that has never been FDA-approved. In June 2025 the court allowed the "patient-specific" copycat marketing claim to proceed while dismissing some claims. These are allegations only and have not been adjudicated.

Eden

Per the BBB snapshot used for this audit, Eden's profile carries an F rating driven by unanswered complaints. A documented Trustpilot complaint (per Trustpilot at the time of writing) describes a customer who paid $576 expecting tirzepatide with a B vitamin and instead received MIC plus methylfolate vials, with the refund denied on the basis that the medical-evaluation form completed had been for B vitamins. The customer reported having been on tirzepatide for the prior six months. Post-cancellation billing complaints in the Eden profile mirror other high-volume compounded-GLP-1 storefronts.

MEDVi

Per the BBB snapshot used for this audit, MEDVi (Medvidi Inc.) holds an F rating, is not BBB-accredited, and shows 311 filed complaints with an average rating of 1.23 out of 5 across 191 reviews. The BBB pattern includes a money-back guarantee window that complainants describe as having shifted from three to five months between cohorts, plus recurring post-cancellation billing. MEDVi's published terms state in capital letters that no refunds will be issued upon cancellation of subscription services.

Peak Wellness Network

Per the VST audit, Peak Wellness Network demonstrates same-day adverse-event support response, scored at the top of the Medication Handling SOP rubric, and shows no warm-vial or shipment-temperature complaints in the review surfaces examined. The triage protocol routes patients to a clinician within hours rather than days.

Shed

Per Trustpilot at the time of writing, Shed shows 4.0 out of 5 across 902 reviews, with generally responsive support and an average BBB record. As a second-tier safe choice, Shed's response pattern is materially better than the F-rated storefronts above without reaching the Peak Wellness tier.

Every provider in this list ships the same molecule. The variable that determines patient outcome is the post-injection support layer. For a maintained ranking that updates as data shifts, see providers ranked by safety + adverse-event response.

Compounded Tirzepatide vs Branded Mounjaro and Zepbound: Side-Effect Profile Compared

The active molecule is the same. The supporting cast is not.

Branded Mounjaro and Zepbound (FDA-approved). Each vial or pen contains tirzepatide plus defined excipients (sodium chloride, sodium phosphate dibasic heptahydrate, water for injection, with HCl or NaOH for pH). Manufacturing runs to current Good Manufacturing Practice; batches are tested for potency and impurities; pharmacovigilance reporting is enforced at the manufacturer level. The adverse-event profile is what is in the prescribing information (Mounjaro PI; Zepbound PI).

Compounded tirzepatide (503A pharmacy). Each batch contains tirzepatide plus variable excipients, often supplemented with cyanocobalamin, methylcobalamin, or B-complex add-ons. There is no GMP requirement at the level applied to branded manufacturing, and inter-batch testing is not standardized. Lilly's open letter documented impurities exceeding ICH Q3B thresholds plus bacterial contamination and elevated endotoxin in tested samples (Eli Lilly Open Letter). FDA does not review compounded drugs for safety, effectiveness, or quality (FDA, Concerns with Unapproved GLP-1).

Tirzepatide vs semaglutide (head-to-head). SURPASS-2 (NEJM 2021) compared tirzepatide and semaglutide 1 mg in 1,879 T2D patients over 40 weeks. Nausea ran 17% to 22% across tirzepatide doses vs 18% on semaglutide; diarrhea 13% to 16% vs 12%; vomiting 6% to 10% vs 8%. Discontinuation due to AEs was 7.7% on tirzepatide vs 4.1% on semaglutide (NEJM 2021, SURPASS-2). Tirzepatide's dual GIP/GLP-1 mechanism produces more weight loss with a similar GI profile; class-level signals (NAION, gallbladder, pancreatitis, thyroid C-cell) apply to both.

The net read: branded tirzepatide carries a more predictable safety profile than compounded tirzepatide, and variability inside the compounded category is wider than the differences between molecules. Tirzepatide produces more weight loss than semaglutide at the cost of slightly higher discontinuation rates.

Tirzepatide Side Effects FAQ

What are the most common tirzepatide side effects?

The most common tirzepatide side effects are gastrointestinal: nausea (12% to 18% vs 4% placebo), diarrhea (12% to 17%), decreased appetite (5% to 11%), constipation (6% to 7%), vomiting (5% to 9%), dyspepsia (5% to 8%), and abdominal pain (5% to 6%) per Mounjaro PI Section 6. Symptoms cluster around dose escalations and are mild to moderate.

What side effects happen on day 1 of tirzepatide?

Day-one tirzepatide side effects are usually mild or absent. Mild nausea most often begins 24 to 48 hours after the first injection rather than on injection day. Patients on the 2.5 mg starter dose typically tolerate the first week well, with the more noticeable cluster appearing after escalation to 5 mg.

How long after a tirzepatide injection do side effects start?

Most tirzepatide side effects begin within 24 to 72 hours of injection. Nausea onset typically falls between four and 24 hours, with peak intensity at 24 to 48 hours. Vomiting trails nausea by one to two days; diarrhea peaks around day four; constipation often begins three to seven days post-injection.

How long do tirzepatide side effects last?

GI side effects typically resolve within one to two weeks at a stable dose. Each escalation can re-trigger the cluster, which is why holding the prior dose for an additional cycle is the standard tolerability tactic. Hair shedding from weight loss typically resolves six to 12 months after weight stabilizes.

Does tirzepatide cause hair loss?

Tirzepatide hair loss occurred in roughly 4% to 6% of users in SURMOUNT-1 vs 1% on placebo, concentrated in women (NEJM 2022, SURMOUNT-1). The mechanism most consistent with the data is telogen effluvium triggered by rapid weight loss, not a direct follicular effect. Hair typically regrows after weight stabilizes; adequate protein, iron, and vitamin D status help.

Can tirzepatide cause vision problems?

Tirzepatide can transiently worsen pre-existing diabetic retinopathy in T2D patients per the Mounjaro label. A 2025 JAMA Network Open cohort identified a class-level NAION signal across semaglutide and tirzepatide users (HR 1.76; absolute 0.04% vs 0.02% over two years). Sudden vision loss is a 911-level symptom.

Is anxiety a tirzepatide side effect?

FDA's January 2024 review across 91 placebo-controlled trials and 107,910 patients found no causal link between GLP-1 receptor agonists and suicidal thoughts or behavior, and the agency requested removal of suicidality warnings from labels (FDA, Drug Safety Communication 2024). Patients with prior depression or anxiety should monitor mood; rapid body composition shifts can independently affect mood.

Does tirzepatide cause cancer?

Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent data; human relevance is unknown. It is contraindicated in patients with personal or family history of MTC or with MEN-2. Outside the thyroid warning, no human cancer signal has been demonstrated for tirzepatide in SURMOUNT or SURPASS programs.

What is tirzepatide pancreatitis risk?

Pancreatitis is a labeled risk; Mounjaro PI Section 5.2 instructs prescribers to discontinue if it is suspected. SURMOUNT-1 reported four adjudication-confirmed cases across treatment and placebo groups, none severe. The red flag is severe constant epigastric pain radiating to the back, often with persistent vomiting; this presentation warrants emergency evaluation.

Are Mounjaro and tirzepatide side effects the same?

Yes, the active molecule and labeled adverse-event profile are the same. Mounjaro is the FDA-approved branded tirzepatide for type 2 diabetes; Zepbound is the branded form for chronic weight management and OSA. Compounded tirzepatide adds variability from non-standard concentrations, additives, and impurities documented in Lilly's testing.

What are tirzepatide compound side effects?

Compounded tirzepatide carries the branded profile plus additive reactions to substances such as cyanocobalamin, dosing errors from non-standard concentrations, ingredient mix-ups (one Trustpilot complaint documents a customer receiving MIC and methylfolate instead of tirzepatide), and impurity-driven adverse events documented in Lilly's open letter. A 2025 JCEM series documented palpitations and morning headaches in compounded users.

Can I keep taking tirzepatide if I have headaches?

Most tirzepatide-related headaches are dehydration-pattern and respond to fluids and small low-fat meals. Severe or new-pattern headaches, particularly with vision changes or confusion, warrant emergency evaluation. Patients on a sulfonylurea or insulin should rule out hypoglycemia. Persistent headaches warrant contacting the prescribing provider before the next dose.

What should I do if I think I'm having a tirzepatide side effect?

Document the symptom (what, when, dose, time of injection), contact the prescribing provider via portal or phone, and file a MedWatch report. For red-flag symptoms (severe abdominal pain radiating to the back, sudden vision loss, anaphylaxis signs, persistent vomiting, suicidal thoughts), bypass the portal and seek emergency care. File MedWatch afterward, particularly for compounded products.

Should I report mild tirzepatide side effects to FDA?

Yes, especially for compounded tirzepatide. FAERS depends on voluntary reports; signals for compounded drugs cannot be detected without them. Reporting is free, anonymous-eligible, and carries no legal exposure. Form FDA 3500B is the consumer version; submit online or by phone at 1-800-FDA-1088.

More from VST GLP-1 Safety

• verified-safe providers
• verify your pharmacy is FDA-compliant